Propanc Biopharma receives Nasdaq delisting notice over minimum bid price, effective Nov. 2

Propanc Biopharma received a Nasdaq delisting notice on October 23, 2026, for failing to meet the $1.00 minimum bid price requirement under Listing Rule 5550(a)(2). Securities are scheduled to be delisted on November 2, 2026, unless the company appeals by October 30, 2026.

Detected & updated continuously · Source: Nebula